Targovax ASA (GB:0RIS) has released an update.
Circio Holding ASA’s CEO and CSO are set to present at key RNA conferences in Frankfurt and San Diego, spotlighting their pioneering circular RNA technology and its potential in gene therapy. Their participation alongside industry giants such as Moderna and Biontech emphasizes Circio’s role as a leader in this innovative field. The company is also advancing a cancer vaccine, TG01, in various clinical trials, supported by prestigious research grants.
For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.
